Rodman & Renshaw Initiates Coverage On Cormedix with Buy Rating, Announces Price Target of $13
Portfolio Pulse from Benzinga Newsdesk
Rodman & Renshaw has initiated coverage on Cormedix (NASDAQ:CRMD) with a Buy rating and set a price target of $13.

August 26, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rodman & Renshaw has initiated coverage on Cormedix with a Buy rating and a price target of $13, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $13 by Rodman & Renshaw suggests a positive sentiment towards Cormedix's stock. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100